Entera Bio Ltd (ENTX) - Total Liabilities
Based on the latest financial reports, Entera Bio Ltd (ENTX) has total liabilities worth $2.17 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Entera Bio Ltd (ENTX) asset resilience to evaluate the company's liquid asset resilience ratio.
Entera Bio Ltd - Total Liabilities Trend (2015–2024)
This chart illustrates how Entera Bio Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Entera Bio Ltd's balance sheet.
Entera Bio Ltd Competitors by Total Liabilities
The table below lists competitors of Entera Bio Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
POLARIS WORKS Inc
KQ:123010
|
Korea | ₩21.88 Billion |
|
Angkor Resources Corp
V:ANK
|
Canada | CA$5.86 Million |
|
Solutions 30 SE
F:30L3
|
Germany | €624.50 Million |
|
Jaiprakash Associates Limited
NSE:JPASSOCIAT
|
India | Rs385.53 Billion |
|
Genesem Inc
KQ:217190
|
Korea | ₩35.31 Billion |
|
Aemulus Holdings Bhd
KLSE:0181
|
Malaysia | RM111.97 Million |
|
Urbana Corporation
TO:URB
|
Canada | CA$94.46 Million |
|
Ersan Alisveris Hizmetleri & Gida Sanayi Ticaret AS
IS:KIMMR
|
Turkey | TL4.65 Billion |
Liability Composition Analysis (2015–2024)
This chart breaks down Entera Bio Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ENTX net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Entera Bio Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Entera Bio Ltd (2015–2024)
The table below shows the annual total liabilities of Entera Bio Ltd from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.31 Million | -5.00% |
| 2023-12-31 | $1.38 Million | +0.44% |
| 2022-12-31 | $1.37 Million | -59.88% |
| 2021-12-31 | $3.42 Million | +54.70% |
| 2020-12-31 | $2.21 Million | -53.76% |
| 2019-12-31 | $4.78 Million | +48.34% |
| 2018-12-31 | $3.23 Million | -92.81% |
| 2017-12-31 | $44.84 Million | +42.19% |
| 2016-12-31 | $31.53 Million | +10.90% |
| 2015-12-31 | $28.43 Million | -- |
About Entera Bio Ltd
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial … Read more